Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma already has the primary FDA approval for a remedy that goes after Claudin 18.2, a protein whose overexpression...
Showing all 2 results
Astellas Pharma already has the primary FDA approval for a remedy that goes after Claudin 18.2, a protein whose overexpression...
Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.
Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.